21 July 2021 – Today, as stated by Dr Ngozi Okonjo-Iweala, Director General of the World Trade Organization, we are on course to produce 11 billion doses of COVID-19 vaccines by the end of this year, which is sufficient to vaccinate the world’s whole adult population. Now, the issue is how these vaccines are going...
Read moreAt this year’s regional World Health Summit in Uganda, we had the pleasure of showcasing the research fellows that IFPMA has been supporting as part of the Chatham House African Public Health Leaders fellowship program since 2016 in an event titled “Will COVID-19 dictate a new paradigm in Africa?” This event was a unique opportunity...
Read moreWe have a realistic hope of producing 11 billion COVID-19 vaccines by the end of 2021 to vaccinate the world’s whole adult population. With increased dose sharing and urgent measures to ensure vaccine equity through COVAX and other bilateral agreements, we would like to see many more vaccines reaching all four corners of the world...
Read more15 July 2021 – IFPMA welcomes the launch of an innovative ‘marketplace’. The new Marketplace aims to accelerate the global production of COVID-19 vaccine doses for COVAX by matching suppliers of critical inputs with vaccine manufacturers who urgently need them to produce vaccines for fair and equitable distribution through COVAX. This initiative spearheaded by Coalition...
Read moreTo put an end to the pandemic, industry was tasked with manufacturing and supplying billions of COVID-19 vaccines, starting from zero. This monumental task is on its way to being achieved, with 11 billion doses forecast for the end of 2021[1]—enough for the world’s adult population, according to the World Bank. However, trade restrictions, amongst...
Read moreOn 7 July 2021, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a (virtual) workshop titled ‘Enabling Manufacturing Capacity in the COVID-19 Pandemic’ [link] with representatives from the leading association bodies representing biotech firms, developing and industrialized countries vaccine manufacturers, as well as innovative biopharmaceutical, generic and biosimilar companies. This first workshop with...
Read moreBoosting production of COVID-19 vaccines is key to ensuring there are enough doses for all populations most at risk. But manufacturing COVID-19 vaccines at the volumes the world needs is a colossal challenge and scarcity of raw materials and trade barriers could upset estimates that 11 billion doses – enough for the world’s adult population...
Read moreThese Data Ethics Principles are intended to help the pharmaceutical industry use data responsibly and sustainably, in alignment with the IFPMA Ethos of care, fairness, respect, and honesty. Ethical data use is critical to innovation, advancing scientific and medical understanding, ensuring patient safety, and improving healthcare for the benefit of individual patients and broader society....
Read more
This blog was originally published on the Media Planet Campaign Value of Vaccines on 25 June 2021. Over the past few decades, the global regulatory environment has become more stringent and demanding to consistently guarantee the quality, safety and efficacy of medicines and vaccines. The increase in requirements by regulatory authorities has not been implemented...
Read more